SCHEMBL7567751

SCHEMBL7567751

c1ccc(-c2cccc3nc[nH]c23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.49
ADORA2A P29274 2/20 0.49
ADORA1 P30542 2/20 0.49
MAP4K4 O95819 1/20 0.43
CSF1R P07333 1/20 0.43
FGFR1 P11362 1/20 0.43
PDGFRA P16234 1/20 0.43
LTK P29376 1/20 0.43
KDR P35968 1/20 0.43
MAPK8 P45983 1/20 0.43
CSNK1A1 P48729 1/20 0.43
LIMK1 P53667 1/20 0.43
CDK5 Q00535 1/20 0.43
ACVR1 Q04771 1/20 0.43
TNK2 Q07912 1/20 0.43
AURKB Q96GD4 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL196912 0.86 PARP1 (0.42) ADORA3ADORA2AADORA1ACVR1SMN1; SMN2
SCHEMBL17231595 0.82 ACVR1 (0.49) ADORA3ADORA2AADORA1MAP4K4CSF1R
SCHEMBL3860255 0.78 ADORA3 (0.46) ADORA3ADORA2AADORA1MAP4K4CSF1R
SCHEMBL4978029 0.78 KDM4E (0.45) ACVR1SMN1; SMN2MAPTNPC1RAB9A
Benzimidazole SCHEMBL28321765 0.77 QPCT (0.50) ADORA3ADORA2AADORA1SMN1; SMN2MAPT
SCHEMBL21323987 0.77 SMN1; SMN2 (0.44) CDK5ACVR1SMN1; SMN2MAPTCYP3A4
SCHEMBL29068393 0.76 PARP1 (0.35) ADORA3ADORA2AADORA1ACVR1SMN1; SMN2
SCHEMBL28053350 0.75 PARP1 (0.58) LIMK1ACVR1CLK4SMN1; SMN2MAPT
SCHEMBL8889421 0.75 ADORA1 (0.51) ADORA3ADORA2AADORA1SMN1; SMN2MAPT
SCHEMBL7090029 0.75 ADORA2A (0.51) ADORA3ADORA2AADORA1FGFR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109566374-B High-yield pea seedling and planting method thereof 刘斌 2021-04-06 CN claimed
CN-109566374-A A kind of high yield pea seedlings and its implantation methods 李靖 2019-04-05 CN claimed
CN-119894230-A Light emitting element, method for manufacturing light emitting element, and display device 三星显示有限公司 2025-04-25 CN disclosed
US-20240174583-A1 PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES DOW TECHNOLOGY INVESTMENTS LLC (US) 2024-05-30 US disclosed
EP-4347544-A1 PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES Dow Technology Investments LLC (US) 2024-04-10 EP disclosed
CN-117242047-A Process for the vapor phase hydrogenation of aldehydes 陶氏技术投资有限责任公司 2023-12-15 CN disclosed
US-11708346-B2 Treatment and prevention of neuropathic pain with P2Y14 antagonists SAINT LOUIS UNIVERSITY (US) 2023-07-25 US disclosed
CN-115103736-B Soldering flux and soldering paste 千住金属工业株式会社 2023-07-14 CN disclosed
US-11584736-B2 Heterocyclic P2Y14 receptor antagonists THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-02-21 US disclosed
WO-2022250790-A1 PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES DOW TECHNOLOGY INVESTMENTS LLC (US) 2022-12-01 WO disclosed
CN-109566351-B Culture medium for improving germination rate 上海派布利克贸易有限公司 2021-10-26 CN disclosed
US-20150376101-A1 HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC 2015-12-31 US disclosed
CN-105073701-A Hetereocyclic agent as catalytic stabilizing agent in a hydroformylation process DOW TECHNOLOGY INVESTMENTS LLC 2015-11-18 CN disclosed
WO-2014149915-A1 HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS DOW TECHNOLOGY INVESTMENTS LLC (US) 2014-09-25 WO disclosed
CN-102236259-A Radiation sensitivity resin composition for display element, interlayer insulation film, protective film and spacer and forming method thereof JSR CORP 2011-11-09 CN disclosed
EP-1234573-A1 Anti-inflammatory pharmaceutical compositions and their manufacturing process Menarini France S.A. (FR) 2002-08-28 EP disclosed
EP-0873292-B1 IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES UNION CARBIDE CHEM PLASTIC (US) 2001-12-19 EP disclosed
EP-0873292-A1 IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1998-10-28 EP disclosed
US-5731472-A HETEROCYCLIC NITROGEN COMPOUNDS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1998-03-24 US disclosed
WO-1997020798-A1 IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1997-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376101-A1 HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS NUDT1, CAT, HRAS ADORA3 3345/4885ADORA2A 1299/4885ADORA1 3187/4885
US-11708346-B2 Treatment and prevention of neuropathic pain with P2Y14 antagonists P2RY14, P2RY4, P2RY13 ADORA3 46/4885ADORA2A 50/4885ADORA1 72/4885
US-11584736-B2 Heterocyclic P2Y14 receptor antagonists P2RY14, P2RY1, P2RY13 ADORA3 43/4885ADORA2A 74/4885ADORA1 33/4885
US-20240174583-A1 PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES ADH1C, ADH5, ALDH2 ADORA3 3820/4885ADORA2A 4014/4885ADORA1 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.